Anzeige
Mehr »
Freitag, 10.10.2025 - Börsentäglich über 12.000 News
3 kritische Rohstoffe. 1 riesiges Becken. $2,26 Mrd. US-Finanzierung: Diese Aktie könnte die Nächste sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWDN | ISIN: US45254E1073 | Ticker-Symbol:
NASDAQ
09.10.25 | 21:59
6,245 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNEERING CORPORATION Chart 1 Jahr
5-Tage-Chart
IMMUNEERING CORPORATION 5-Tage-Chart

Aktuelle News zur IMMUNEERING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
IMMUNEERING Aktie jetzt für 0€ handeln
26.09.Immuneering: Telefonkonferenz zu neuen Studiendaten bei Bauchspeicheldrüsenkrebs3
26.09.Immuneering to host call on pancreatic cancer treatment data2
26.09.Immuneering Corporation: Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 20251
25.09.Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings957OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
25.09.Mizuho bestätigt Outperform-Rating für Immuneering nach positiven Studiendaten5
25.09.Biggest stock movers Thursday: RIG, IMRX, and more5
25.09.Immuneering Reveals Pricing Of 18.96 Mln Shares Public Offering At $9.23/Shr5
25.09.Immuneering legt Preis für 175-Millionen-Dollar-Angebot auf 9,23 US-Dollar je Aktie fest5
25.09.Immuneering prices $175 million public offering at $9.23 per share1
25.09.Immuneering Corporation: Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi12
24.09.Immuneering surges 40% on mid-stage atebimetinib data in pancreatic cancer1
24.09.Immuneering announces public offering, $25M private placement with Sanofi; shares up 55%10
24.09.Immuneering kündigt öffentliches Angebot an und sichert sich 25-Millionen-Dollar-Investment von Sanofi23
24.09.Immuneering stock soars after reporting 86% survival rate in cancer trial2
24.09.Immuneering announces public offering and $25 million Sanofi investment4
24.09.Immuneering reports strong survival data in pancreatic cancer trial3
24.09.Immuneering Corp - 8-K, Current Report1
24.09.Immuneering Corporation: Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP153- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects...
► Artikel lesen
24.09.Immuneering Corporation: Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi7
15.09.Needham raises Immuneering stock price target to $11 on PDAC study1
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1